FDA Drug Approvals
3 articles on FDA Drug Approvals, written by Shotlee and medically reviewed for clinical accuracy.
FDA Approves Foundayo: GLP-1 Weight Loss Pill with Fewer Use Restrictions
Eli Lilly's Foundayo, a new GLP-1 weight loss pill, just received FDA approval with key advantages: take it anytime without food or water restrictions. Backed by trials showing 12% body weight loss over 72 weeks, it aims to make obesity treatment more accessible. Compare pricing, side effects, and how it stacks up against Wegovy and injectables.
5 min read
Lilly's $1.5B Orforglipron Inventory Grows Ahead of FDA Obesity Nod
Eli Lilly is stockpiling $1.5 billion worth of its oral obesity drug orforglipron to avoid the supply shortages that hampered early GLP-1 launches. With an expected FDA decision on April 10, the company aims for a swift global rollout against Novo Nordisk's Wegovy pill. This strategic move signals big changes in accessible weight loss therapy.
5 min read
FDA Approvals for 2025
In 2025, the FDA approved 46 novel therapeutic agents from its Center for Drug Evaluation and Research, marking a slight dip from the five-year average but remaining above historical norms. Cancer led approvals, with advancements in modalities like kinase inhibitors and gene therapies. The year also introduced new programs and faced staffing challenges under changing leadership.
13 min read